Accreditation Expired
NASH: What’s behind the link with T2D and obesity?
GlobalA discussion of the associations between NASH, type 2 diabetes and obesity
NASH: What’s behind the link with T2D and obesity?
People with type 2 diabetes or obesity are at higher risk of developing non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH). Some estimates report a prevalence of NAFLD of 60% in people with type 2 diabetes, rising to 78% in those who also have obesity. So what’s behind this link?
In this video, Professor Giulio Marchesini explores the relationships between NAFLD, type 2 diabetes and obesity and offers advice for healthcare professionals caring for people with one or more of these conditions.
By completing this module you can qualify for 0.25 CME credits. To claim your credits, you must watch the video and successfully pass the post-module assessment.
Pre-Activity Information
Hepatologists, endocrinologists, diabetologists, gastroenterologists, GPs
This educational activity is intended for an international audience of non-US and non-UK HCPs.
Describe the association of NASH with type 2 diabetes and obesity and how this relates to management strategies
Faculty: Professor Giulio Marchesini
| Type of affiliation / financial interest | Name of commercial company |
|---|---|
| Advisory Board | Novartis, Eli Lilly, Gilead, MSD, Pfzier, Astra-Zeneca |
Staff Disclosures
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.
This module was accredited on the 1st April 2022 and will expire on the 1st April 2023.
The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.